A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis [clinicaltrials:NCT00002321]
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis [clinicaltrials:NCT00002321]
Bio2RDF identifier
NCT00002321
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002321
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To determine the MTD an ...... his patient
population.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase I Study of the Safety ...... ytomegalovirus (CMV) Retinitis
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Patients will receive s ...... d the MTD will be determined.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Acquired Immunodeficiency Syndrome
Antiviral Agents
Drug Therapy, Combination
Ganciclovir
Interleukin-2
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-06-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002321
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study of the Safety ...... ytomegalovirus (CMV) Retinitis
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
CS-L293-10
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
1994-10-01T00:00:00Z
identifier
clinicaltrials:NCT00002321
title
A Phase I Study of the Safety ...... ytomegalovirus (CMV) Retinitis
@en
type
label
A Phase I Study of the Safety ...... s [clinicaltrials:NCT00002321]
@en